{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:28:21Z","timestamp":1793824101387,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific research project of Education Department of Liaoning Province","award":["LJ212410163025"],"award-info":[{"award-number":["LJ212410163025"]}],"id":[{"id":"https:\/\/ror.org\/0022v2454","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Science and technology plan joint project of Liaoning Province","award":["2024-MSLH-436"],"award-info":[{"award-number":["2024-MSLH-436"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11095-026-04188-z","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:37:42Z","timestamp":1790105862000},"page":"3759-3778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liposomal Formulation of a Tetravalent Oxaliplatin Prodrug: Preparation and Antitumor Efficacy"],"prefix":"10.1007","volume":"43","author":[{"given":"Shiyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"1","key":"4188_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2023.108346","volume":"35","author":"P Sun","year":"2024","unstructured":"Sun P, Li Z, Zhang D, Zeng W, Zheng Y, Mei L, et al. Multifunctional biodegradable nanoplatform based on oxaliplatin prodrug cross-linked mesoporous polydopamine for enhancing cancer synergetic therapy. Chin Chem Lett. 2024;35(1):108346. https:\/\/doi.org\/10.1016\/j.cclet.2023.108346.","journal-title":"Chin Chem Lett"},{"issue":"6","key":"4188_CR2","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1016\/j.apsb.2025.04.006","volume":"15","author":"S Wu","year":"2025","unstructured":"Wu S, Tang Q, Fang W, Sun Z, Zhang M, Liu E, et al. Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery. Acta Pharm Sin B. 2025;15(6):3226\u201342. https:\/\/doi.org\/10.1016\/j.apsb.2025.04.006.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4188_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1634\/theoncologist.9-1-8","volume":"9","author":"A Ibrahim","year":"2004","unstructured":"Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist. 2004;9(1):8\u201312. https:\/\/doi.org\/10.1634\/theoncologist.9-1-8.","journal-title":"Oncologist"},{"issue":"12","key":"4188_CR4","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1007\/s13346-025-01833-9","volume":"15","author":"K Abhang","year":"2025","unstructured":"Abhang K, Dighe S, Katari O, Yadav V, Jain S. Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer. Drug Deliv Transl Res. 2025;15(12):4550\u201370. https:\/\/doi.org\/10.1007\/s13346-025-01833-9.","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"4188_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/17474124.2019.1573143","volume":"13","author":"R Fritsch","year":"2019","unstructured":"Fritsch R, Hoeppner J. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma. Expert Rev Gastroenterol Hepatol. 2019;13(4):285\u201391. https:\/\/doi.org\/10.1080\/17474124.2019.1573143.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4188_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2024.215774","volume":"508","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Shi P, Wang C, Sun Y, Gao C. Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs. Coord Chem Rev. 2024;508:215774. https:\/\/doi.org\/10.1016\/j.ccr.2024.215774.","journal-title":"Coord Chem Rev"},{"issue":"1","key":"4188_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41467-023-36469-1","volume":"14","author":"X Wen","year":"2023","unstructured":"Wen X, Zhang R, Hu Y, Wu L, Bai H, Song D, et al. Controlled Sequential in Situ Self-Assembly and Disassembly of a Fluorogenic Cisplatin Prodrug for Cancer Theranostics. Nat Commun. 2023;14(1):800. https:\/\/doi.org\/10.1038\/s41467-023-36469-1.","journal-title":"Nat Commun"},{"issue":"9","key":"4188_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092460","volume":"15","author":"AD Aputen","year":"2023","unstructured":"Aputen AD, Elias MG, Gilbert J, Sakoff JA, Gordon CP, Scott KF, et al. Versatile platinum(IV) prodrugs of naproxen and acemetacin as chemo-anti-inflammatory agents. Cancers. 2023;15(9):2460. https:\/\/doi.org\/10.3390\/cancers15092460.","journal-title":"Cancers"},{"key":"4188_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1191534","author":"T Tang","year":"2023","unstructured":"Tang T, Gong Y, Gao Y, Pang X, Liu S, Xia Y, et al. A pH-responsive liposomal nanoplatform for co-delivery of a Pt(IV) prodrug and cinnamaldehyde for effective tumor therapy. Front Bioeng Biotechnol. 2023. https:\/\/doi.org\/10.3389\/fbioe.2023.1191534.","journal-title":"Front Bioeng Biotechnol"},{"key":"4188_CR10","doi-asserted-by":"publisher","DOI":"10.1039\/D5CS00440C","author":"Z Li","year":"2025","unstructured":"Li Z, Li M, Lu J. Biomimetic liposomes in drug delivery: from design mechanisms to applications. Chem Soc Rev. 2025. https:\/\/doi.org\/10.1039\/D5CS00440C.","journal-title":"Chem Soc Rev"},{"key":"4188_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2022.102757","volume":"309","author":"M Dymek","year":"2022","unstructured":"Dymek M, Sikora E. Liposomes as biocompatible and smart delivery systems \u2013 the current state. Adv Colloid Interface Sci. 2022;309:102757. https:\/\/doi.org\/10.1016\/j.cis.2022.102757.","journal-title":"Adv Colloid Interface Sci"},{"issue":"4","key":"4188_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/pharmaceutics8040036","volume":"8","author":"S Ong","year":"2016","unstructured":"Ong S, Chitneni M, Lee K, Ming L, Yuen K. Evaluation of extrusion technique for nanosizing liposomes. Pharmaceutics. 2016;8(4):36. https:\/\/doi.org\/10.3390\/pharmaceutics8040036.","journal-title":"Pharmaceutics"},{"key":"4188_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2019.124202","volume":"586","author":"M Jo","year":"2020","unstructured":"Jo M, Park K-M, Park J-Y, Yu H, Choi SJ, Chang P-S. Microfluidic Assembly of Mono-Dispersed Liposome and Its Surface Modification for Enhancing the Colloidal Stability. Colloids Surf Physicochem Eng Asp. 2020;586:124202. https:\/\/doi.org\/10.1016\/j.colsurfa.2019.124202.","journal-title":"Colloids Surf Physicochem Eng Asp"},{"issue":"3","key":"4188_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10544-023-00671-1","volume":"25","author":"V Di Francesco","year":"2023","unstructured":"Di Francesco V, Boso DP, Moore TL, Schrefler BA, Decuzzi P. Machine learning instructed microfluidic synthesis of curcumin-loaded liposomes. Biomed Microdevices. 2023;25(3):29\u201342. https:\/\/doi.org\/10.1007\/s10544-023-00671-1.","journal-title":"Biomed Microdevices"},{"issue":"12","key":"4188_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/nano11123440","volume":"11","author":"E Jaradat","year":"2021","unstructured":"Jaradat E, Weaver E, Meziane A, Lamprou DA. Microfluidics technology for the design and formulation of nanomedicines. Nanomaterials (Basel). 2021;11(12):3440. https:\/\/doi.org\/10.3390\/nano11123440.","journal-title":"Nanomaterials (Basel)"},{"key":"4188_CR16","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.2147\/IJN.S166219","volume":"13","author":"A Casad\u00f3","year":"2018","unstructured":"Casad\u00f3 A, Sagrist\u00e1 ML, Mora Gim\u00e9nez M. A Novel Microfluidic Liposomal Formulation for the Delivery of the SN-38 Camptothecin: Characterization and in Vitro Assessment of Its Cytotoxic Effect on Two Tumor Cell Lines. Int J Nanomedicine. 2018;13:5301\u201320. https:\/\/doi.org\/10.2147\/IJN.S166219.","journal-title":"Int J Nanomedicine"},{"key":"4188_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.actbio.2020.12.024","volume":"121","author":"I Arduino","year":"2021","unstructured":"Arduino I, Liu Z, Rahikkala A, Figueiredo P, Correia A, Cutrignelli A, et al. Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique. Acta Biomater. 2021;121:566\u201378. https:\/\/doi.org\/10.1016\/j.actbio.2020.12.024.","journal-title":"Acta Biomater"},{"key":"4188_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.addr.2020.09.003","volume":"154\u2013155","author":"J Di","year":"2020","unstructured":"Di J, Xie F, Xu Y. When liposomes met antibodies: drug delivery and beyond. Adv Drug Deliv Rev. 2020;154\u2013155:151\u201362. https:\/\/doi.org\/10.1016\/j.addr.2020.09.003.","journal-title":"Adv Drug Deliv Rev"},{"key":"4188_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120571","author":"D Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es D. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120571.","journal-title":"Int J Pharm"},{"issue":"4","key":"4188_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/08982104.2019.1668010","volume":"30","author":"C Has","year":"2020","unstructured":"Has C, Sunthar P. A comprehensive review on recent preparation techniques of liposomes. J Liposome Res. 2020;30(4):336\u201365. https:\/\/doi.org\/10.1080\/08982104.2019.1668010.","journal-title":"J Liposome Res"},{"key":"4188_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121897","volume":"622","author":"Y Huang","year":"2022","unstructured":"Huang Y, Dai X, Guan Z, Liu D, Ren L, Chen M, et al. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking. Int J Pharm. 2022;622:121897. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121897.","journal-title":"Int J Pharm"},{"key":"4188_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120923","volume":"606","author":"X Kuang","year":"2021","unstructured":"Kuang X, Hu Y, Chi D, Zhang H, He Z, Jiang Y, et al. Self-stabilized Pt(IV) amphiphiles by precise regulation of branch length for enhanced chemotherapy. Int J Pharm. 2021;606:120923. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120923.","journal-title":"Int J Pharm"},{"issue":"10","key":"4188_CR23","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1021\/acs.molpharmaceut.5c01110","volume":"22","author":"R Li","year":"2025","unstructured":"Li R, Yin X, Chong C, Li Y, Yao Q, Mu Y, et al. Exploring the relationships between targeted structures and antitumor activities of nuclear-targeted polypeptide-functionalized platinum(IV) prodrugs. Mol Pharm. 2025;22(10):6349\u201356. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01110.","journal-title":"Mol Pharm"},{"issue":"15","key":"4188_CR24","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1039\/C7DT04537A","volume":"47","author":"S Theiner","year":"2018","unstructured":"Theiner S, Grabarics M, Galvez L, Varbanov HP, Sommerfeld NS, Galanski MS, et al. The impact of whole human blood on the kinetic inertness of Platinum(IV) prodrugs \u2013 an HPLC-ICP-MS study. Dalton Trans. 2018;47(15):5252\u20138. https:\/\/doi.org\/10.1039\/C7DT04537A.","journal-title":"Dalton Trans"},{"key":"4188_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2020.111353","volume":"217","author":"D Gibson","year":"2021","unstructured":"Gibson D. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end? J Inorg Biochem. 2021;217:111353. https:\/\/doi.org\/10.1016\/j.jinorgbio.2020.111353.","journal-title":"J Inorg Biochem"},{"key":"4188_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2021.213991","volume":"442","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang Z, Deng Z, Zhu G. Recent advances in the synthesis, stability, and activation of Platinum(IV) anticancer prodrugs. Coord Chem Rev. 2021;442:213991. https:\/\/doi.org\/10.1016\/j.ccr.2021.213991.","journal-title":"Coord Chem Rev"},{"issue":"42","key":"4188_CR27","doi-asserted-by":"publisher","first-page":"18556","DOI":"10.1002\/anie.202005362","volume":"59","author":"Q Cao","year":"2020","unstructured":"Cao Q, Zhou D-J, Pan Z-Y, Yang G-G, Zhang H, Ji L-N, et al. CAIXplatins: highly potent Platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors. Angew Chem Int Ed Engl. 2020;59(42):18556\u201362. https:\/\/doi.org\/10.1002\/anie.202005362.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"28","key":"4188_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202505930","volume":"64","author":"H Meng","year":"2025","unstructured":"Meng H, Wang J, Wen H, Xu Z, Luo L, Lin W, et al. Evoking simultaneous ferroptosis and apoptosis by a dual-locked platinum (IV) prodrug for synergistic chemo-immunotherapy. Angew Chem Int Ed. 2025;64(28):e202505930. https:\/\/doi.org\/10.1002\/anie.202505930.","journal-title":"Angew Chem Int Ed"},{"issue":"3","key":"4188_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001813","volume":"9","author":"M Kie\u00dfler","year":"2021","unstructured":"Kie\u00dfler M, Plesca I, Sommer U, Wehner R, Wilczkowski F, M\u00fcller L, et al. Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. J Immunother Cancer. 2021;9(3):e001813. https:\/\/doi.org\/10.1136\/jitc-2020-001813.","journal-title":"J Immunother Cancer"},{"key":"4188_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jconrel.2025.02.006","volume":"380","author":"H Liu","year":"2025","unstructured":"Liu H, Zou J, Li X, Ge Y, He W. Drug delivery for platinum therapeutics. J Control Release. 2025;380:503\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.006.","journal-title":"J Control Release"},{"key":"4188_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106556","volume":"187","author":"X Chang","year":"2023","unstructured":"Chang X, Bian M, Liu L, Yang J, Yang Z, Wang Z, et al. Induction of immunogenic cell death by novel platinum-based anticancer agents. Pharmacol Res. 2023;187:106556. https:\/\/doi.org\/10.1016\/j.phrs.2022.106556.","journal-title":"Pharmacol Res"},{"key":"4188_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1229829","author":"A Ota","year":"2023","unstructured":"Ota A, Mochizuki A, Sou K, Takeoka S. Evaluation of a static mixer as a new microfluidic method for liposome formulation. Front Bioeng Biotechnol. 2023. https:\/\/doi.org\/10.3389\/fbioe.2023.1229829.","journal-title":"Front Bioeng Biotechnol"},{"key":"4188_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105191","volume":"91","author":"X Xiu","year":"2024","unstructured":"Xiu X, Ma S, Li Z, Li Z, Li X, Ruan Y, et al. Novel 3D integrated microfluidic device: design, construction, and application to the preparation of liposomes for vaccine delivery. J Drug Deliv Sci Technol. 2024;91:105191. https:\/\/doi.org\/10.1016\/j.jddst.2023.105191.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4188_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121347","volume":"611","author":"E Weaver","year":"2022","unstructured":"Weaver E, O\u2019Connor E, Cole DK, Hooker A, Uddin S, Lamprou DA. Microfluidic-mediated self-assembly of phospholipids for the delivery of biologic molecules. Int J Pharm. 2022;611:121347. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121347.","journal-title":"Int J Pharm"},{"issue":"8","key":"4188_CR35","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1039\/D3NA01073B","volume":"6","author":"M Maeki","year":"2024","unstructured":"Maeki M, Kimura N, Okada Y, Shimizu K, Shibata K, Miyazaki Y, et al. Understanding the effects of ethanol on the liposome bilayer structure using microfluidic-based time-resolved small-angle X-ray scattering and molecular dynamics simulations. Nanoscale Adv. 2024;6(8):2166\u201376. https:\/\/doi.org\/10.1039\/D3NA01073B.","journal-title":"Nanoscale Adv"},{"issue":"31","key":"4188_CR36","doi-asserted-by":"publisher","first-page":"40543","DOI":"10.1021\/acsami.4c01368","volume":"16","author":"D Mendanha","year":"2024","unstructured":"Mendanha D, Casanova MR, Gimondi S, Ferreira H, Neves NM. Microfluidic-derived docosahexaenoic acid liposomes for targeting glioblastoma and its inflammatory microenvironment. ACS Appl Mater Interfaces. 2024;16(31):40543\u201354. https:\/\/doi.org\/10.1021\/acsami.4c01368.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"4188_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57\u201374. https:\/\/doi.org\/10.3390\/pharmaceutics10020057.","journal-title":"Pharmaceutics"},{"issue":"4","key":"4188_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/pharmaceutics17040440","volume":"17","author":"A Sharma","year":"2025","unstructured":"Sharma A, Al Amin M, Kshetri MB, Alqarni S, Jogadi W, Solmen J, et al. PEGylation effects on amphiphilic platinum(IV) complexes: influence on uptake, activation, and cytotoxicity. Pharmaceutics. 2025;17(4):440\u201354. https:\/\/doi.org\/10.3390\/pharmaceutics17040440.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4188_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-022-00661-z","volume":"5","author":"P Fronik","year":"2022","unstructured":"Fronik P, Gutmann M, Vician P, Stojanovic M, Kastner A, Heffeter P, et al. A Platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance. Commun Chem. 2022;5(1):46. https:\/\/doi.org\/10.1038\/s42004-022-00661-z.","journal-title":"Commun Chem"},{"issue":"2","key":"4188_CR40","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1021\/acs.jmedchem.4c02263","volume":"68","author":"T Babu","year":"2025","unstructured":"Babu T, Muthuramalingam RPK, Chng WH, Yau JNN, Acharya S, Engelmayer N, et al. Multitargeting Pt(IV) derivatives of cisplatin or oxaliplatin inhibit tumor growth in mice without inducing neuropathic pain. J Med Chem. 2025;68(2):1608\u201318. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02263.","journal-title":"J Med Chem"},{"issue":"11","key":"4188_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112484","volume":"14","author":"F Sommonte","year":"2022","unstructured":"Sommonte F, Weaver E, Mathew E, Denora N, Lamprou DA. In-house innovative \u201cdiamond shaped\u201d 3D printed microfluidic devices for lysozyme-loaded liposomes. Pharmaceutics. 2022;14(11):2484. https:\/\/doi.org\/10.3390\/pharmaceutics14112484.","journal-title":"Pharmaceutics"},{"key":"4188_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111766","volume":"203","author":"X Kuang","year":"2021","unstructured":"Kuang X, Chi D, Li J, Guo C, Yang Y, Zhou S, et al. Disulfide bond based cascade reduction-responsive Pt(IV) nanoassemblies for improved anti-tumor efficiency and biosafety. Colloids Surf B Biointerfaces. 2021;203:111766. https:\/\/doi.org\/10.1016\/j.colsurfb.2021.111766.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"4188_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2181746","volume":"30","author":"X Li","year":"2023","unstructured":"Li X, Guan S, Li H, Li D, Liu D, Wang J, et al. Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis. Drug Deliv. 2023;30(1):2181746. https:\/\/doi.org\/10.1080\/10717544.2023.2181746.","journal-title":"Drug Deliv"},{"issue":"10","key":"4188_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102180","volume":"12","author":"A Garanina","year":"2024","unstructured":"Garanina A, Vishnevskiy D, Chernysheva A, Malinovskaya J, Lazareva P, Semkina A, et al. The internalization pathways of liposomes, PLGA, and magnetic nanoparticles in neutrophils. Biomedicines. 2024;12(10):2180. https:\/\/doi.org\/10.3390\/biomedicines12102180.","journal-title":"Biomedicines"},{"issue":"23","key":"4188_CR45","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2174\/1381612828666220607105746","volume":"28","author":"E Lu","year":"2022","unstructured":"Lu E, Gareev I, Yuan C, Liang Y, Sun J, Chen X, et al. The mechanisms of current platinum anticancer drug resistance in the glioma. Curr Pharm Des. 2022;28(23):1863\u20139. https:\/\/doi.org\/10.2174\/1381612828666220607105746.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"4188_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1208\/s12249-024-02988-3","volume":"26","author":"L Bhute","year":"2024","unstructured":"Bhute L, Dighe S, Katari O, Yadav V, Jain S. Bifunctional oxaliplatin (IV) prodrug based pH-sensitive PEGylated liposomes for synergistic anticancer action against triple negative breast cancer. AAPS PharmSciTech. 2024;26(1):2. https:\/\/doi.org\/10.1208\/s12249-024-02988-3.","journal-title":"AAPS PharmSciTech"},{"key":"4188_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinorgbio.2015.05.012","volume":"150","author":"M Ravera","year":"2015","unstructured":"Ravera M, Gabano E, Zanellato I, Bonarrigo I, Alessio M, Arnesano F, et al. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs. J Inorg Biochem. 2015;150:1\u20138. https:\/\/doi.org\/10.1016\/j.jinorgbio.2015.05.012.","journal-title":"J Inorg Biochem"},{"key":"4188_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jinorgbio.2016.03.005","volume":"160","author":"S G\u00f6schl","year":"2016","unstructured":"G\u00f6schl S, Varbanov HP, Theiner S, Jakupec MA, Galanski MS, Keppler BK. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. J Inorg Biochem. 2016;160:264\u201374. https:\/\/doi.org\/10.1016\/j.jinorgbio.2016.03.005.","journal-title":"J Inorg Biochem"},{"issue":"13","key":"4188_CR49","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1002\/adfm.201504899","volume":"26","author":"L Feng","year":"2016","unstructured":"Feng L, Gao M, Tao D, Chen Q, Wang H, Dong Z, et al. Cisplatin-prodrug-constructed liposomes as a versatile theranostic nanoplatform for bimodal imaging guided combination cancer therapy. Adv Funct Mater. 2016;26(13):2207\u201317. https:\/\/doi.org\/10.1002\/adfm.201504899.","journal-title":"Adv Funct Mater"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04188-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04188-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04188-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:50:18Z","timestamp":1793821818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04188-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4188"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04188-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no conflict of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}